Back to news

SyndromeX has several drug candidates targeting Metabolic Syndrome (comprised of Dyslipidemia, Type II Diabetes, Upper Body Obesity, Hypertension and Coronary Heart Disease). The pharmaceutical company has two proprietary lead compounds with primary indications for Dyslipidemia (M1001) and Type II Diabetes (M1002). They are fatty acid compounds which are non-metabolized analogies of Omega-3 fatty acids, which are available in fish and widely used as a “healthy” food supplement.